Lv2
110 积分 2025-07-16 加入
Neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy for human epidermal growth factor receptor 2 positive breast cancer: a real-world retrospective single-institutional study in China
2个月前
已完结
BRAF Mutation in Papillary Thyroid Cancer: Pathogenic Role, Molecular Bases, and Clinical Implications
2个月前
已完结
HER2 Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer
2个月前
已完结
Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase II trial
2个月前
已完结
Trastuzumab deruxtecan (T‐Dxd) for advanced breast cancer patients (ABC), regardless HER2 status: a phase II study with biomarkers analysis (DAISY)
2个月前
已关闭
Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies
2个月前
已完结
Understanding the spectrum of HER2 status in breast cancer: From HER2-positive to ultra-low HER2
2个月前
已完结
HER2-Low Breast Cancers
2个月前
已完结
A Phase I/Ib Trial of PD 0332991 (Palbociclib) and T-DM1 in HER2-Positive Advanced Breast Cancer After Trastuzumab and Taxane Therapy
2个月前
已完结
Co-targeting CDK 4/6 and C-MYC/STAT3/CCND1 axis and inhibition of tumorigenesis and epithelial-mesenchymal-transition in triple negative breast cancer by Pt(II) complexes bearing NH3 as trans-co-ligand
2个月前
已完结
Tumor Glycolytic Profiling Through 18F-FDG PET/CT Predicts Immune Checkpoint Inhibitor Efficacy in Advanced NSCLC
皖公网安备34019202002308
